

# Injectables that Lower Glucose



Class/Main Action	Name	Dose Range	Considerations
<b>GLP-1 Agonist</b> “Incretin Mimetic” <ul style="list-style-type: none"> <li>Increases insulin release with food</li> <li>Slows gastric emptying</li> <li>Promotes satiety</li> <li>Suppresses glucagon</li> </ul>	exenatide (Byetta) exenatide XR (Bydureon)	5 or 10 mcg BID (renally excreted) 2mg 1x a week (renally excreted)	<b>Side effects for all:</b> Nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med.  <b>Black box warning:</b> Thyroid C-cell tumor warning for liraglutide, exenatide XR, albiglutide, and dulaglutide (avoid if family history of medullary thyroid cancer, notify MD of hoarseness, throat lump).  Lowers A1c 0.5 – 1.6% Wt loss of ~ 3lbs
	liraglutide (Victoza)	0.6 - 1.8 mg daily	
	lixisenatide (Adlyxin)	10 mg daily for 2 weeks. Then increase to 20 mg daily.	
	albiglutide (Tanzeum)	30 and 50 mg 1x a week pen injector	
	dulaglutide (Trulicity)	0.75 and 1.5 mg 1x a week pen injector	
<b>Amylin Mimetic</b> <ul style="list-style-type: none"> <li>Slows gastric emptying</li> <li>Suppresses glucagon</li> <li>Promotes satiety</li> </ul>	pramlintide (Symlin)	Type 1: 15 - 60 mcg; Type 2: 60 - 120 mcg  immediately before major meals	For Type 1 or 2 on insulin.  <b>Black box warning:</b> severe hypoglycemic risk 3 hrs post injection. Prevent hypoglycemia, decrease insulin dose when starting pramlintide. Side effects: nausea, weight loss.  Lowers A1c 0.5 – 1%

The information listed here are general guidelines only; please consult prescribing information for details.

# Insulin/Injectable Combos

Download **FREE CDE® Coach App** for latest Pocketcard versions and priority notifications | [DiabetesEd.Net](http://DiabetesEd.Net)



Name	Combines	Considerations
<b>IDegLira</b>	<p>Insulin degludec (IDeg or Tresiba) Ultra long insulin +</p> <p>Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA)</p>	<p>Once daily fixed ratio pen injection – Dose range 1 to 50. Pre-filled pen contains fixed IDeg/liraglutide ratio of 100 units/ 3.6 mg per mL. Max dose is 50 = 50 units IDeg + 1.8 mg liraglutide.</p> <ul style="list-style-type: none"> <li>• IDegLira dose titrated based on fasting BG (see package insert)</li> <li>• Dose prescribed matches the number show on the pen.</li> <li>• Common starting dose is 10 IDegLira for insulin naïve pts and 16 IDegLira for pts already on basal insulin or GLP-1 RA.</li> </ul> <p>When dialed to 10, IDegLira pen delivers 10 units IDeg + 0.36 mg liraglutide. When dialed to 16, IDegLira pen delivers 16 units IDeg + 0.6 mg liraglutide.</p>
<b>iGlarLixi</b>	<p>Insulin glargine (Lantus) Solostar 10 – 60 units day + Pen (Soliqua)</p> <p>Lixisenatide (Adlyxin) 5 – 20 µg GLP-1 Receptor Agonist</p>	<p>Once daily fixed ratio pen injection before breakfast based on Fasting BG levels. 2 different iGlarLixi Solostar pen dose ratios available:</p> <ul style="list-style-type: none"> <li>• Yellow pen = 10 – 40 units glargine + 5 – 20 µg lixisenatide Delivers glargine/lixisenatide at 2/1 ratio (for insulin naïve pts)</li> <li>• Green pen- 30 – 60 units glargine + 10 – 20µg lixisenatide Delivers glargine/lixisenatide at 3/1 ratio (for pts already on basal insulin)</li> </ul>

## Inhaled Insulin

Action	Insulin Name	Dose Range	Onset	Peak	Duration	Considerations
Bolus – Rapid-acting	Afrezza Inhaled regular human insulin	4, 8, and 12 unit cartridges before meals	15 mins	1 hr	3 hrs	Assess lung function before starting. Avoid in chronic lung disease — acute bronchospasm risk. Side effects: hypoglycemia, cough, throat irritation.

*These are general guidelines only; please consult prescribing info. Observe precautions of each component drug.*

REV 8/2016 © 2016